Hudson Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Hudson Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-80	Closed	-$845	–	68
2023 Q4	$845	Hold	80	–	–	﹤0.01%	64
2023 Q3	$1.58K	Hold	80	–	–	﹤0.01%	67
2023 Q2	$6.1K	Hold	80	–	–	﹤0.01%	66
2023 Q1	$7.53K	Hold	80	–	–	﹤0.01%	64
2022 Q4	$7.76K	Hold	80	–	–	﹤0.01%	65
2022 Q3	$21K	Hold	80	–	–	0.01%	59
2022 Q2	$15K	Hold	80	–	–	0.01%	65
2022 Q1	$8K	Hold	80	–	–	﹤0.01%	67
2021 Q4	$13K	Hold	80	–	–	﹤0.01%	70
2021 Q3	$22K	Hold	80	–	–	0.01%	65
2021 Q2	$32K	Hold	80	–	–	0.01%	64
2021 Q1	$43K	Hold	80	–	–	0.02%	64
2020 Q4	$30K	Hold	80	–	–	0.01%	64
2020 Q3	$30.1K	Hold	80	–	–	0.01%	65
2020 Q2	$39K	Hold	80	–	–	0.02%	75
2020 Q1	$29K	Hold	80	–	–	0.02%	66
2019 Q4	$56K	Hold	80	–	–	0.03%	71
2019 Q3	$51.2K	Buy	80 +5	+7%	+$3.97K	0.03%	72
2019 Q2	$65.6K	Hold	75	–	–	0.04%	80
2019 Q1	$43.3K	Hold	75	–	–	0.03%	79
2018 Q4	$21K	Hold	75	–	–	0.02%	76
2018 Q3	$36K	Hold	75	–	–	0.03%	75
2018 Q2	$34K	Hold	75	–	–	0.02%	77
2018 Q1	$44K	Hold	75	–	–	0.03%	75
2017 Q4	$47K	Buy	+75	New	+$53.9K	0.03%	84

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Hudson Capital Management's TCRT Position: Q1 2024 in Review

Hudson Capital Management sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 80 shares — an estimated $845 sold.

Hudson Capital Management first reported a position in TCRT in Q4 2017 and held it in 25 quarters. The position peaked at $65.6K in Q2 2019. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Hudson Capital Management reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Hudson Capital Management sold 80 Alaunos Therapeutics shares in Q1 2024, an estimated $845.
Hudson Capital Management first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 25 quarters.
Hudson Capital Management's Alaunos Therapeutics position peaked at $65.6K in Q2 2019.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Hudson Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.